HASBROUCK HEIGHTS, N.J., August 21 /CNW/ - Nymox Pharmaceutical
Corporation (NASDAQ: NYMX) today announced that further clinical results from
the Company's studies of NX-1207 for benign prostatic hyperplasia (BPH) will
be presented at the meeting of the Western Section of the American Urological
Association (AUA) to be held in Scottsdale, Arizona in October. The paper is
authored by leading clinical research investigators from U.S. clinical trials
of NX-1207. Further specific details on the upcoming presentation will be
announced at a later date.
The Company previously completed three U.S. trials for NX-1207, including
most recently a Phase 2 double-blind, placebo controlled, randomized
multi-site U.S. study, which showed positive efficacy and safety results for
NX-1207 after 3 months in patients with BPH. Overall, patients treated with
NX-1207 showed after 3 months a mean improvement of 9.35 points in AUA Symptom
Score values, the standard scale used to evaluate BPH drugs and treatments.
This improvement compares favorably to the 3.5 to 5 point reported in
published studies of currently approved drugs for BPH and reached statistical
significance when compared to placebo. Subjects treated with NX-1207 also
showed an overall statistically significant reduction in mean prostate volume.
The results of the trial demonstrated the excellent safety and side effect
profile of NX-1207. Subjects treated with NX-1207 had no serious side effects.
In particular, patients given NX-1207 had no (0%) significant sexual side
The Company previously announced that papers concerning NX-1207 clinical
studies will be presented in September at the meeting of the South Central
Section of the AUA in Colorado Springs and at the meeting of the New England
Section of the AUA in Boston and in October at the meeting of the Mid-Atlantic
Section of the AUA in Bermuda.
The company also recently reported positive long-term outcome results
from an 8-19 month study of 116 unselected subjects from 26 U.S. clinical
sites in a blinded placebo-controlled study, which reached statistical
significance (p=.028). In that study, overall without further NX-1207
treatment, patients initially treated with NX-1207 showed a total pooled mean
improvement of 7.4 points in the primary outcome endpoint of AUA Symptom Score
The AUA Symptom Score is a standardized measurement of BPH symptoms and
includes data on 1) sensations of incomplete emptying of the bladder; 2) need
to urinate frequently; 3) stopping and starting during urination; 4) urgent
need to urinate; 5) weakness of urinary stream; 6) need to push or strain
during urination; and 7) urination during sleep (nocturia). Published studies
of currently approved drugs for BPH show AUA Symptom Score improvement in the
3.5 to 5 point range.
BPH afflicts approximately half of men over age 50 and close to 90% of
men by age 80. The disorder causes difficulties with urination associated with
aging, such as urination at night, urge to void frequently, hesitancy, weak
stream, and other problems.
More information about Nymox is available at www.nymox.com, email:
firstname.lastname@example.org, or 800-936-9669.
This press release contains certain "forward-looking statements" as
defined in the United States Private Securities Litigation Reform Act of 1995
that involve a number of risks and uncertainties. There can be no assurance
that such statements will prove to be accurate and the actual results and
future events could differ materially from management's current expectations.
The conduct of clinical trials and the development of drug products involve
substantial risks and uncertainties and actual results may differ materially
from expectations. Promising early results do not ensure that later stage or
larger scale clinical trials will be successful or will proceed as expected.
Such factors are detailed from time to time in Nymox's filings with the United
States Securities and Exchange Commission and other regulatory authorities.
For further information:
For further information: Nymox Pharmaceutical Corporation Roy Wolvin,